Moleculin Biotech is trading at $2.26 (+6.60%) following a strong intraday rebound, despite a lack of company-specific news, earnings, or FDA catalysts.
- The upward move appears consistent with a broader biotech-sector bid, as the XBI is up 2.31% and sentiment across the group improves.
- Despite the daily gain, the stock remains highly volatile and continues to show weak longer-term performance trends.